Dysregulation of MAL (myelin and lymphocyte protein) has been implicated in several malignancies including esophageal, ovarian, and cervical cancers. The MAL protein functions in apical transport in polarized epithelial cells; therefore, its disruption may lead to loss of organized polarity characteristic of most solid malignancies. Bisulfite sequencing of the MAL promoter CpG island revealed hypermethylation in breast cancer cell lines and 69% of primary tumors analyzed compared with normal breast epithelial cells. Differential methylation between normal and cancer DNA was confined to the proximal promoter region. In a subset of breast cancer cell lines including T47D and MCF7 cells, promoter methylation correlated with transcriptional silencing that was reversible with the methylation inhibitor 5-aza-2 ¶-deoxycytidine. In addition, expression of MAL reduced motility and resulted in a redistribution of lipid raft components in MCF10A cells. MAL protein expression measured by immunohistochemistry revealed no significant correlation with clinicopathologic features. However, in patients who did not receive adjuvant chemotherapy, reduced MAL expression was a significant predictive factor for disease-free survival. These data implicate MAL as a commonly altered gene in breast cancer with implications for response to chemotherapy.
Introduction
Cancer can be caused by the accumulation of both genetic and epigenetic alterations frequently leading to downstream changes in gene expression patterns. Epigenetic changes do not alter the DNA sequence, and therapeutics targeted at reversing epigenetic modifications hold the potential to reactivate expression of previously silenced genes, potentially altering the malignant phenotype (1, 2) . Furthermore, these epigenetic changes can be used as markers for detection of malignant cells in bodily fluids (3) . In the present study, we identify MAL (myelin and lymphocyte protein) as a novel epigenetically regulated gene in breast cancer.
Although 70% to 80% of CpGs in human cells are normally methylated, cytosines within CpG islands are protected from methylation (4) . Even as CpG islands are typically unmethylated, the areas flanking the islands are methylated and act as barriers protecting against aberrant promoter methylation (5, 6). In neoplasia, the barriers protecting the promoter CpG islands are commonly overridden with de novo methylation believed to begin at the distal ends of the island and then progressively spreading into the core (5) . Therefore, cancer-associated hypermethylation is a dynamic process that may change with time, disease state, or treatment.
MAL was first identified in a screen for genes differentially expressed during T-cell development (7) . The MAL gene encodes a 17 kDa transmembrane protein selectively found in glycolipid-enriched membrane microdomains or lipid rafts (8) (9) (10) . In this context, MAL appears to function in glycolipidenriched membrane-mediated apical sorting of membrane and secretory proteins in polarized epithelial cells (11, 12) . The MAL protein is expressed on the apical face of most types of human epithelia consistent with its role in polarized secretion (13) . Moreover, its location in membrane microdomains suggests that it may have a role in cell signaling (9, 14) . Interest in this gene in our laboratory arose from a microarray study showing that MAL is the most differentially expressed transcript between serous ovarian cancers with good versus poor outcome (15) . This finding led us to examine MAL transcriptional regulation in ovarian 6 and breast cancer. Using bisulfite genomic sequencing, we examined the methylation profile of the MAL promoter region in both benign and breast cancer specimens. Our results show that hypermethylation of the MAL promoter is common in primary breast cancer and that, in some cases, this methylation appears to impair gene transcription. Further, we describe a cancer-specific methylation pattern that should guide future epigenetic studies at this locus.
Finally, we begin to analyze the functional consequences of MAL protein expression in cell culture and in primary breast tumors.
Results

MAL Promoter Hypermethylation in Breast Cancer Cell Lines Is Associated with Gene Silencing
Interest in MAL gene regulation arose from our microarray profiling study showing that it was the most differentially expressed gene between two groups of advanced serous ovarian cancers matched for stage: cancers from patients with >7-year survival versus <3-year survival after initial diagnosis (15) . Although we observed evidence of promoter methylation in ovarian cancers cell lines and in primary ovarian tumors, 6 in parallel, we also examined breast cancer cell lines. MAL has a promoter CpG island of f1,500 bp that contains 116 CpG dinucleotides and extends into the first intron. Our initial bisulfite sequence analysis covered 22 CpG dinucleotides spanning the region from -48 to +82 relative to the start of MAL transcription (Fig. 1A) . Comparing a series of cultured mammary epithelial cells ranging from benign primary cells derived from breast reductions [human mammary epithelial cells (HMEC)], immortalized cell lines from breast reductions, and cancer cell lines, we found that the methylation status in this region was highly variable (Fig. 1B and C) . HMEC cultures from four different reduction specimens (age range, showed no evidence of methylation in this region. Four immortalized cell lines each had detectable methylation with the MCF10A line showing the highest and the telomerase immortalized DU99 line the lowest level of methylation. Of the six cancer lines analyzed, the estrogen receptor (ER)-positive MCF7 and T47D cells had the highest levels of methylation. It is notable that, even in these long-cultured cell lines, methylation at any given CpG was not necessarily uniform over the 22 dinucleotide pairs assayed. These data indicate that the MAL promoter region may be a common target for hypermethylation in breast cancer.
To assess the effects of promoter methylation on MAL mRNA expression, we treated a series of cultured benign and breast cancer cells with the methylation inhibitor 5-aza-2 ¶-deoxycytidine (DAC) and then measured mRNA expression by quantitative real-time PCR (RT-PCR). We observed induction (10-to 40-fold) of MAL mRNA transcription in the cancer cell lines T47D, MCF7, and ZR75-1 but either very little or no increase in the benign DU99 line and primary mammary epithelial cells (Fig. 1D) . MAL expression was also strongly induced by DAC in the immortalized cell line MCF10A. Comparing methylation status to reactivation by DAC (Fig. 1D) , we found that only the cell lines with the highest degree of promoter methylation induced MAL expression after treatment with the methylation inhibitor. The status of three of the most differentially methylated residues located at -46, -44, and -42 relative to the start of transcription correlate most closely with reactivation by DAC. Basal expression of MAL in these cells was also highly variable (Fig. 1D) . The three primary HMEC cultures had nearly identical MAL mRNA levels, whereas each of the four cell lines with DAC inducible expression had very low basal levels (MCF10A, T47D, MCF7, and ZR75-1). Two of the cancer lines (BT474 and HCC1937) expressed particularly high levels of MAL, f15-and 150-fold higher than the HMEC cultures, respectively. The partial methylation observed in these two lines indicates that epigenetic control is only one factor regulating expression of this gene in breast cells.
Methylation of the MAL Promoter in Primary Breast Tumors
To determine if the pattern of methylation seen in the cancer cell lines was also present in breast tumors, we analyzed a series of 36 primary breast cancer specimens and matched constitutive DNA (from peripheral blood lymphocytes) by bisulfite sequencing. We observed varying degrees of methylation and classified the cancers into three categories based on the average percent methylation quantitated by phosphorimaging of the sequencing gels: heavily methylated (defined as an average methylation level >40%), partially methylated (5-40%), and unmethylated (<5%) ( Fig. 2A) . Of 36 primary cancers analyzed, 7 of 36 (19%) were heavily methylated, 18 of 36 (50%) exhibited partial methylation, and the remaining 11 (31%) had no evidence of methylation. In summary, we detected MAL promoter methylation in 25 of 36 (69%) of the primary tumors analyzed. All but one of the matched lymphocyte DNA samples were completely unmethylated in this region.
The breast cancer specimens used in this study are typical of the disease and contained a heterogeneous admixture of cells. To confirm that hypermethylation of MAL was derived from the cancer epithelium, we analyzed DNA extracted from laser capture microdissected cancer and normal breast epithelia (from reduction mammoplasty specimens with no evidence of cancer). DNA suitable for bisulfite sequencing analysis was obtained from 10 cancers and 4 normal specimens. Comparing DNA extracted from bulk tumor versus the same tumor subjected to laser capture microdissection indicates that the methylation signal was derived from the malignant epithelial cells (Fig. 2B) . In the example shown, the cancer scored initially as partially methylated (28% as measured by phosphorimaging) appears to be completely methylated in this region after microdissection of the tumor epithelia. Importantly, DNA from microdissected normal breast epithelia exhibited no methylation in this region (Fig. 2B) . Although only primary cancers that contained at least 50% cancer cells were used in the analysis of bulk tumor DNA, it is likely that our scoring of partial methylation underestimates the degree of methylation in these cases. Absence of methylation in normal breast epithelium suggests that hypermethylation in cancer is associated with the oncogenic process. Furthermore, methylation analysis of pure ductal carcinoma in situ samples (with no coexisting invasive component) showed hypermethylation in three of five specimens, indicating that this epigenetic event can occur early during neoplastic progression (Supplementary Fig. S1 ).
Differential Methylation in the MAL Promoter Is Confined to the Proximal Promoter Region
In designing a methylation-specific PCR assay for this region, we noticed that placement of the upstream primer was critical in obtaining results consistent with the sequence analysis described above. This led to additional sequencing of the promoter region from a series of specimens that revealed an abrupt transition in the methylation profile f350 bp upstream of the transcription start site. We analyzed 4 microdissected normal breast epithelial specimens, 4 benign immortalized mammary epithelial cell lines, and 36 normal lymphocyte samples (from breast cancer patients) to determine the position and frequency of constitutive methylation in this region ( Supplementary Fig. S2 ). Upstream of this transition zone, the majority of normal breast epithelia, normal lymphocytes, and tumors were partially or fully methylated. Figure 2C shows the position of the transition point in both a normal breast and a breast cancer sample taken from two separate patients, showing the appearance of partial methylation upstream of the transition point in the normal specimen. This non-disease-associated methylation extends to at least -621 by our sequence analysis (Fig. 2D) . Therefore, the region of differential or diseaseassociated methylation is confined to a relatively small region of the proximal promoter.
Expression of MAL Results in Altered Raft Composition and Reduced Motility
To our knowledge, expression of the MAL protein in breast epithelial cells has yet to be shown. By immunohistochemistry using a well-characterized monoclonal antibody (mAb; refs. 8, 9, 13), we were able to detect MAL in normal breast epithelium from reduction mammoplasty specimens ( Supplementary  Fig. S3 ). In other epithelial cell types, the MAL protein has been shown to localize to cholesterol-enriched membrane microdomains characterized by their resistance to detergent solubilization. We examined this localization in breast epithelial cell lines expressing endogenous (HCC1937) or exogenous (MCF10A stably transfected with a V5-tagged construct) MAL protein. Fractionation of detergent-extracted cells by sucrose gradient velocity sedimentation followed by immunoblot analysis showed endogenous MAL protein in HCC1937 cells predominantly in the insoluble fraction (Fig. 3A, left) . Detection of the lipid raft resident protein flotillin-1 (16) in this fraction confirmed the biochemical localization.
To begin to investigate the consequences of MAL expression, we next established a MCF10A line stably expressing MAL with a COOH-terminal V5 tag. Parental MCF10A cells are hypermethylated at the MAL promoter and express low levels of mRNA ( Fig. 1D ) and protein (data not shown). Fractionating these cells indicated that the exogenous MAL protein localized to both the soluble and the insoluble compartments. Interestingly, probing these same fractions for flotillin-1 indicated that MAL expression induces a compartmental change in this protein. Whereas flotillin-1 was found entirely in the soluble fraction in the vector control line (under G418 selection), introduction of MAL produced a dramatic redistribution of this protein into the insoluble fraction (Fig. 3A,  right) . This suggests that decreased MAL expression may affect the protein composition of membrane microdomains.
To determine if expression of MAL induces a phenotypic effect related to cancer progression, we monitored cell motility using a wound-healing assay in stably transfected cells expressing either MAL or a vector control plasmid. MALexpressing MCF10A cells showed a significant decrease in cell motility assessed by the ability to completely close a wound in the cell monolayer ( Fig. 3B and C) . In the transformed MCF7 and MD468 cells, a similar trend was observed in which MAL expression caused a reduction in motility ( Supplementary  Fig. S4 ). However, this decrease did not reach statistical significance. Reduced motility was not attributable to changes in proliferation or cell cycle as measured by propidium iodide staining and flow cytometry (data not shown).
Correlation of MAL Protein Expression with Clinicopathologic Features and Outcome
Because promoter methylation has a direct effect on gene transcription levels, we initially looked for a relationship between MAL promoter methylation and mRNA expression. Analyzing 36 primary tumors by quantitative RT-PCR, we observed varying levels of mRNA expression with the average MAL expression in the methylated tumors (288 F 62, expression normalized to h 2 -microglobulin) being lower than that observed in those lacking methylation (468 F 171); however, this difference did not reach statistical significance (P = 0.23; Supplementary Fig. S5 ). This finding suggests that MAL promoter methylation, although common in breast cancer, cannot exclusively account for the observed differences in MAL expression. Further, of the cancers that exhibited methylation (either partial or heavy), the majority were nuclear hormone receptor positive, whereas all of the unmethylated cancers for which data were available were ER/progesterone receptor-negative (Supplementary Table S1 ).
Our earlier data showed that the level of methylation is not an absolute predictor for basal mRNA expression, specifically in the HCC1937 and BT474 cell lines, which contain promoter methylation but have high levels of MAL mRNA (Fig. 1D) . Consequently, we examined MAL protein expression as a more direct measurement to determine the dynamics of MAL in breast cancer. We evaluated MAL expression by immunohistochemical analysis in a representative sample of 122 banked frozen breast cancers resected at Duke University Medical Center between 1990 and 1998. In all staining runs, controls included a normal breast specimen and a normal kidney (distal and collecting tubules express high levels, whereas glomeruli and proximal tubules are negative) as positive and negative controls and to normalize for interassay variability in intensity. In addition, 20 cancers were included (in a blinded fashion) in more than one staining run to assure reproducibility. Within the invasive cancer samples, we observed highly variable MAL protein levels, from undetectable to abundance similar to the kidney distal tubule epithelium (Fig. 4 ). Tissues were categorized as negative for MAL staining in the malignant breast epithelium (Fig. 4A) or positive for MAL (Fig. 4B) . Many of the cancers contained infiltrating inflammatory cells that reacted with the antibody. We observed no significant relationship between MAL protein expression and common clinicopathologic variables (Table 1) . Disease-free survival, with an average follow-up of 96 months, trended toward better outcome in patients with MAL-expressing cancers but did not reach statistical significance (Fig. 4C) .
Whereas MAL expression does not have strong prognostic value, predictive value is of equal or greater importance as a determinant of who will derive benefit from adjuvant chemotherapy. Overall, we observed no difference in diseasefree survival based on the delivery of chemotherapy alone ( Fig. 5A) . MAL staining did not identify a difference in the subpopulation of patients that received adjuvant cytotoxic therapy (Fig. 5B) . However, in the group of patients who were not treated, absence of MAL staining was a significant predictor of disease progression (Fig. 5C ). MAL-positive and MALnegative tumors from patients who did not receive adjuvant chemotherapy were not significantly different based on age, nodal status, tumor size, or hormone receptor status (Supplementary Table S2 ), indicating that the MAL protein may be an independent predictor of benefit from chemotherapy.
Discussion
Hypermethylation of gene promoters leading to transcriptional silencing is associated with the onset and progression of cancer. Identification of genes that are epigenetically regulated in cancer can provide targets for early detection and therapeutics. In this study, we identified MAL as a novel epigenetically regulated gene in breast cancer. MAL, a component of lipid rafts, plays a central role in the reorganization of these membrane microdomains for signaling and/or intracellular protein transport in epithelial cells (11, 12, 14) . Martin-Belmonte et al. (17) showed that RNA interference directed against MAL impaired apical transport leading to the accumulation of secretory proteins in the Golgi and loss of polarity in Madin-Darby canine kidney cells. Loss of polarized growth is a common hallmark of malignant progression; loss or reduced MAL expression through epigenetic mechanisms may prove to be an important early event in the transformation process. Our observation of MAL hypermethylation in ductal carcinoma in situ samples strongly supports this possibility.
We observed hypermethylation of the MAL promoter in all of the breast cancer cell lines (6 of 6) and 69% of primary tumors analyzed relative to cultured primary breast epithelial cells, patient matched lymphocytes, and normal breast tissue from healthy donors. When attempting to correlate the levels of MAL expression to promoter methylation, we found that this association could be made for some but not all cell lines or primary tumors. The consequences of promoter methylation on MAL expression could be shown in breast cell culture in that MAL mRNA expression was inducible by DAC only in hypermethylated cell lines. In a series of cell lines, we observed a correlation between the degree of hypermethylation and the induction of the MAL transcript, specifically in MCF7, T47D, ZR75-1, and MCF10A cells. MAL expression was not affected in primary mammary epithelial cells that have no detectable methylation. Further, methylated cell lines that responded to DAC had basal levels of MAL transcripts that were 10-to 40-fold below that found in benign HMEC cultures. Inhibiting methylation in these cells induced MAL to a level comparable with primary breast epithelia. Notably, two breast cancer cell lines did not follow this trend, HCC1937 and BT474. The MAL promoter is hypermethylated, yet both lines exhibit high basal levels of expression that were not further induced by DAC treatment. The presence of completely unmethylated residues, for example, in CpG sites 1 and 3 of HCC1937 (Fig. 1C) , may indicate that the critical CpG residues for the transcriptional regulation of this gene are not sufficiently methylated in these lines. Alternatively, these cell lines may contain high levels of certain transcription factors allowing for the elevated expression of MAL. Ultimately, high basal expression in the presence of partial methylation in these two lines indicates that promoter methylation is not the only mechanism regulating MAL expression in breast cells.
This study is the first describing the epigenetic regulation of MAL in breast cancer; however, Mimori et al. (18) showed that treatment of esophageal cancer cell lines with DAC and trichostatin A up-regulated MAL gene expression in 12 of 13 cell lines examined. More recently, a genome-wide search (19) found that MAL was frequently hypermethylated in colon cancer correlating with reduced expression. These reports and our current data suggest that epigenetic silencing of MAL may be a common event involved in the initiation and progression of epithelial cancers.
The pattern and amount of promoter hypermethylation can be very heterogeneous leading to varying degrees of gene silencing in tumor cells. The level of promoter methylation can vary not only within a given cell population but also between alleles of a given gene and from one CpG site to another in a single CpG island (20) . Given the heterogeneous nature of promoter methylation, we thought it necessary to consider not only the presence or absence of methylation in a few CpG dinucleotides within the MAL promoter but also the pattern of methylation over a relatively large portion of the promoter region. We surveyed >800 bp of sequence, which included the Fig. S5 ). We observed a strong correlation of MAL hypermethylation with ER-positive (P = 0.003) and progesterone receptor-positive (P = 0.006) cancers (Supplementary Table S1 ). This was consistent with our cell line data showing that the hormone receptor-positive MCF7, T47D, and ZR75-1 lines are all methylated and MAL expression could be reactivated by DAC. This is not the first finding that links ER/progesterone receptor status with promoter methylation in breast cancer. A recent study by Wei et al. (22) showed that methylation of the BRCA1 promoter was more frequently observed in women with high-grade ERnegative and progesterone receptor-negative tumors. If reduced MAL expression is associated with loss of polarity, then it is possible that the higher percentage of ER-positive cancers that exhibit MAL hypermethylation is indicative of a greater selection for this property during the neoplastic progression of luminal type cancers compared with ER-negative cancers more likely to be of the basal subtype. Whether this reflects the varied etiology of these cancers or a cell lineage phenomenon is not known.
From available gene expression array data (23), we found that MAL is contained within a group of coordinately regulated genes (metagene) that are immune cell related. MAL was first discovered as a T-cell-specific protein. Therefore, it was formally possible that the bulk of MAL transcription in breast cancer could be attributed to infiltrating inflammatory cells. To address this, we compared levels of MAL expression with the expression of T-cell-restricted genes (CD2 and CD27) by quantitative RT-PCR and array analysis (data not shown). Although some cancers with very high levels of MAL also coexpressed T-cell markers, this association was not invariant. Together with microdissection data, immunohistochemistry, immunoblotting, and cell culture results, we are confident that breast epithelial cells can and do express MAL mRNA and protein. However, elevated expression of MAL mRNA seen in some cancers that are bulk extracted may be more indicative of the presence of immune cells in these tissues than an upregulation of the gene in malignant epithelia.
Disruption of MAL expression has been implicated in the etiology of several human cancer types. Down-regulation of MAL expression was observed in colon (19) , cervical (24) , renal, and thyroid (13, 25) neoplasms when compared with their respective benign epithelium. In esophageal cancer, MAL was suggested to be a tumor suppressor gene based on studies showing that MAL expression repressed the formation of tumors induced by TE3 cells in nude mice, inhibited cell motility, and induced apoptosis via the Fas signaling pathway (18) . Furthermore, MAL expression was indicative of disease outcome and prognosis for patients with T-cell lymphoma (26), Hodgkin's lymphoma (27) , and serous ovarian cancer (15) . The function of MAL in normal or neoplastic breast epithelial cells is unknown; however, its location in the detergent-insoluble fraction in HCC1937 cells suggests that, similar to other cell types, it plays an integral role in membrane microdomains. Exogenous expression of the MAL protein in the MCF10A cell line resulted in its accumulation in the detergent-insoluble fraction. Further, flotillin-1, another lipid raft component, was redistributed from the soluble to the insoluble fraction when MAL was expressed in these cells, suggesting that MAL may be critical for organizing the composition and likely the function of these microdomains in breast epithelial cells. Similar to an esophageal cancer cell line (18) , expression of MAL in breast cells also reduced motility. However, we did not observe a similar effect on growth or cell cycle resulting from MAL expression in these cells.
Given the complexity of the methylation pattern at this locus and the availability of a high-quality mAb, we examined MAL expression at the protein level in a series of primary frozen breast specimens. Consistent with mRNA expression of cultured HMEC, we found that benign breast epithelia expressed easily detectable MAL protein by immunohistochemical staining. Categorizing 122 primary cancers based on the absence or presence of staining in malignant epithelial cells, no significant correlations were found with standard clinicopathologic variables including age, stage, nodal status, tumor size, hormone receptor status, or disease-free survival. Over 40% of the patients in this study did not receive adjuvant cytotoxic chemotherapy. In this subgroup, absence of MAL protein expression was highly associated with shorter diseasefree survival (P = 0.003). In patients who were treated with chemotherapy, MAL staining was not predictive. As expected, patients who did not receive chemotherapy were older, had smaller tumors, and were more frequently node-negative and hormone receptor-positive (Supplementary Table S2 ). These findings suggest that lack of MAL protein expression might identify a subgroup of breast cancer patients that would benefit from receiving adjuvant chemotherapy. We are currently investigating whether loss of MAL protein expression makes breast cancer cells more responsive to the standard cytotoxic chemotherapies used in our cohort of patients.
To our knowledge, this is the first article implicating MAL expression in the development of breast cancer. Our data, and that of others, support the importance of the proper regulation of MAL expression in a variety of cancers. The role of MAL in maintaining proper cell polarity, secretion, signaling, and motility may define a new functional class of tumor suppressor genes and thus warrants further study with respect to the development, progression, and treatment of cancer.
Materials and Methods
Methylation Analyses
Sodium bisulfite modification of DNA was done based on a protocol by Grunau et al. (28) with additional modifications to accommodate a 96-well format (29) . Briefly, 1 Ag genomic DNA was denatured with 3 mol/L NaOH for 20 min at 42jC followed by deamination in saturated sodium bisulfite/ 10 mmol/L hydroquinone (Sigma) solution for 4 h at 55jC. Nuclease-free water was added to the samples in bisulfite solution and transferred to a Montage PCR 96 96-well filtration plate (Millipore). All remaining steps of the protocol were done in the Montage PCR 96 96-well filtration plate using a vacuum manifold (Millipore Multiscreen Vacuum Manifold) and an in-house vacuum source. The DNA was desalted with nucleasefree water three times followed by desulfonation with 0.1 mol/L NaOH and a final wash step with water. The DNA was recovered in 50 AL of 10 mmol/L Tris-HCl (pH 8.0) by using a plate shaker to release the DNA from the filtration matrix for 10 min (Vortex Genie 2) followed by transfer to individual tubes and storage at 4jC.
For sequencing, bisulfite-treated genomic DNA was PCR amplified with primers specific for bisulfite-converted sequences. Primer sequences (5 ¶-3 ¶) include F1 GGGAGTAATTTTT-TATTTTTAGGTAGA (forward), F3 GTTAGATTTATAGTTT-TTAGTTTTGG (forward), R2 ACCAAAAACCACTCACAA-ACTC (reverse), R3 AAACCACTAAACAAAATACTACCC (reverse), R4 CCAAAACTAAAAACTATAAATCTAAC (reverse), and R5 CAAAACAAAACCACTTTAATCAAA (reverse). The PCR products were resolved on agarose gels and purified using Sigma GenElute spin columns (Sigma) followed by cycle sequencing (Thermo Sequenase Radiolabeled Terminator Cycle Sequencing Kit; Amersham Biosciences). Following resolution of the sequencing reactions on denaturing polyacrylamide gels, dried gels were exposed to radiographic film (Kodak X-OMAT MR) and/or a PhosphorImager screen followed by a quantitative determination of relative band intensity using the Storm PhosphorImager System and ImageQuant Software (GE Healthcare Life Sciences). Specimens with average methylation ranging from 40% to 100% were classified as heavily methylated, those exhibiting methylation levels between 5% and 40% were partially methylated, and specimens with methylation levels <5% were designated as unmethylated. Methylation of ductal carcinoma in situ samples was analyzed by fluorescence-based cycle sequencing using Big Dye Terminator Cycle Sequencing Reagents (Applied Biosystems).
Laser Capture Microdissection
The Veritas laser capture microdissected system (Arcturus Engineering) was used to obtain pure populations of ductal carcinoma in situ, normal, or malignant breast epithelial cells. The normal breast tissue specimens were obtained from women undergoing reduction mammoplasty with no evidence of cancer. Sections (7 Am) were stained with hematoxylin and areas to be captured were selected based on cytologic morphology (Supplementary Fig. S6 ). DNA was extracted using the Puregene DNA extraction kit (Gentra Systems) followed by sodium bisulfite modification and sequence analysis as described above, with the exception that the DNA was recovered in 25 AL of 10 mmol/L Tris-HCl (pH 8.0).
Cell Culture and Treatment
The human breast cancer cell lines MCF7, MDA-MB-468, T47D, ZR75-1, BT474, and HCC1937 were obtained from the American Type Culture Collection and maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies). Benign breast epithelial cultures and lines were also used in these studies and were cultured in DFCI medium (30) . Primary HMECs were obtained from women undergoing reduction mammoplasty with no evidence of cancer. The 26NC cell line is a chemically immortalized (dimethylbenzanthracene) derivative of the 26N primary culture and has been maintained in our laboratory for >10 years (31 Both benign and cancer cells were treated with 5 Amol/L DAC (decitabine/DAC, Sigma) from a 200 mmol/L stock dissolved in 50% acetic acid for 24 h. All treatments were carried out in complete medium with cells in logarithmic growth phase. Control cultures were treated with the vehicle only. Following treatment, cells were harvested and total RNA was extracted using the Qiagen RNeasy Mini Kit. Total RNA (1 Ag) was then reverse transcribed using Transcriptor RT (Roche). Subsequent RT-PCRs (TaqMan Assays-on-Demand; Applied Biosystems, MAL, Hs00242748_m1) were done using a 1:15 dilution of the cDNA according to the manufacturer's recommendation on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems), with the exception that a 25 AL reaction volume was used with 50 total cycles. The relative expression level of MAL was obtained for each sample by normalization to the expression level of the human h 2 -microglobulin gene (Applied Biosystems). All MAL and B2M expression analyses were done in parallel. Results are from two separate experiments done in triplicate.
Generating Stable Transfectants
For stable transfection of MAL, the MAL coding sequence (bases 60-518; accession no. NM002371) was PCR amplified, sequence verified, and inserted into the Gateway entry vector pDONR 221 (Invitrogen). Once in pDONR 221, the coding region was subsequently cloned into pDEST 40, a COOHterminal V5-tagged Gateway expression vector (Invitrogen) using the LR recombination reaction following the manufacturer's protocol. Transfection of pDEST 40-MALV5 into MCF7 or MCF10A cells was done using Lipofectin (Invitrogen) or GenePORTER (Genlantis), respectively, following the supplier's protocol. Control cell lines were established by transfecting an empty expression plasmid, pcDNA3.1(+) (Invitrogen), into the respective parental cell lines. The efficiency for each transfection was analyzed by a green fluorescent protein-containing plasmid. The selection of positive clones was carried out with 500 Ag G418 sulfate (CellGro). After 3 weeks, several clones of MCF7 or MCF10A cells expressing stably MALV5 were isolated by cloning cylinders and expanded under continued selection.
Detergent Extraction Procedures
Glycolipid-enriched membranes were isolated by standard procedures (32) . Cells were grown to confluence in 100 mm dishes, rinsed with PBS, and lysed for 20 min in 1 mL of 25 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 5 mmol/L EDTA, and 1% Triton X-100 at 4jC. The lysate was scraped from the dishes with a rubber cell scraper, the dishes were rinsed with 1 mL of the same buffer at 4jC, and the lysate was homogenized by passing the sample through a 22-gauge needle. The extract was finally brought to 40% sucrose in a final volume of 4 mL and sequentially overlaid with 6 mL of 30% sucrose and 2 mL of 5% sucrose. Gradients were centrifuged for 18 h at 39,000 rpm at 4jC in a Beckman SW40 rotor. The opalescent band at the 5% to 30% sucrose interface, containing rafts, was collected as the Triton X-100-insoluble fraction, whereas the 40% sucrose layer containing the load was harvested as the Triton X-100-soluble fraction. Aliquots were then subjected to immunoblot analysis.
Immunoblot Analyses
For immunoblot analysis, samples were subjected to SDS-PAGE in 8% to 16% gradient acrylamide gels under reducing conditions and transferred to Whatman nitrocellulose membranes. After blocking with 10% (w/v) nonfat dry milk, 0.1% (v/v) Tween 20 in PBS for 1 h, membranes were incubated for 2 h in the presence of anti-MAL 6D9 mAb (8, 9) , anti-V5 (Invitrogen), and anti-flotillin-1 (Transduction Laboratories) or 1 h with an anti-actin antibody (Sigma). After several washings, membranes were incubated for 1 h with goat anti-mouse IgG coupled to horseradish peroxidase, washed extensively, and developed using the Western Lightning Chemiluminescence Kit (Perkin-Elmer).
In vitro Wound-Healing Assay
Cell motility was measured using an in vitro wound-healing assay. Cells were seeded on 6-well tissue culture plates and grown to 100% confluence. Wounds were created by scraping the monolayer with a sterile pipette tip (1 mm O.D.). The wounded monolayers were washed twice with PBS to remove cell debris then incubated in fresh medium, imaged through a Nikon Diaphot inverted microscope, and photographed with a Nikon D50 digital camera at 0, 12, 24, 36, and 48 h. Replicate areas were wounded and measurements of the wound closure were made on the digital images.
Immunohistochemical Analysis
Tissue specimens were obtained under an institutional review board-approved protocol from patients undergoing breast surgery at Duke University Medical Center between 1990 and 1998. Data for the survival analysis and clinicopathologic features listed in Table 1 were obtained from 122 invasive breast cancer patients. Percent disease-free survival was measured from the date of initial diagnosis to the date of first recurrence or the date of last follow-up. Noncancerous tissue samples were obtained from reduction mammoplasties. These specimens were flash frozen and maintained at -135jC. Sections of 5 Am thickness were cut, air dried, and fixed in acetone for 5 min. Immunologic detection using the anti-MAL 6D9 mAb (8, 9) or mouse IgG (Vector Laboratories) was done on all specimens. Human kidney was used as a positive control in all staining runs, and lymphocytes, which express MAL, were used as internal positive control cells. Binding of the antibody was visualized using the ABC (Vector Laboratories) immunoperoxidase system according to the manufacturer's recommendations. Cancers were considered positive for MAL protein if >20% of the malignant epithelial cells had detectable cytoplasmic staining.
Statistical Analysis
For comparison of average gene expression levels between samples, two-tailed t tests were used to calculate significance. Significant differences between clinicopathologic features of patient subgroups (methylated versus unmethylated, MAL+ versus MAL-, and Chemo+ versus Chemo-) were calculated using m 2 analysis or Fisher's exact test when groups contained n < 5. Survival curves were generated for primary breast cancer patients with the Kaplan-Meier estimate and log-rank test using the Prism statistical software (GraphPad).
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